Arimoclomol
- Generic Name
- Arimoclomol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20ClN3O3
- CAS Number
- 289893-25-0
- Unique Ingredient Identifier
- EUT3557RT5
- Background
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
- Indication
Investigated for use/treatment in amyotrophic lateral sclerosis (ALS), diabetes mellitus type 2, neurologic disorders, and neuropathy (diabetic).
- Associated Conditions
- -
- Associated Therapies
- -
Early Access Program With Arimoclomol in US Patients With NPC
- Conditions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- ZevraDenmark
- Registration Number
- NCT04316637
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸UCSF Benioff Children's Hospital and Research Center/ UCSF, Oakland, California, United States
🇺🇸Children's Hospital of Orange County (CHOC), Orange, California, United States
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 121
- Registration Number
- NCT04049097
- Locations
- 🇬🇧
University College of London, London, United Kingdom
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Phoenix Neurological Associates, Phoenix, Arizona, United States
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 120
- Registration Number
- NCT03836716
- Locations
- 🇺🇸
University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States
🇪🇸Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11, Barcelona, Spain
🇬🇧Leonard Wolfson Experimental Neurology Centre, London, United Kingdom
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 39
- Registration Number
- NCT03746587
- Locations
- 🇮🇳
Maulana Azad Medical College, New Delhi, India
🇮🇳King Edward Memorial Hospital, Mumbai, Maharashtra, India
🇮🇳Jaslok Hospital and Reseach Centre, Mumbai, Maharashtra, India
Arimoclomol in Amyotropic Lateral Sclerosis
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 245
- Registration Number
- NCT03491462
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Providence Brain & Spine Institute, Portland, Oregon, United States
🇸🇪Umeå University Hospital, Umeå, Sweden
Study of Arimoclomol in Inclusion Body Myositis (IBM)
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 152
- Registration Number
- NCT02753530
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇬🇧University College of London, London, United Kingdom
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- ZevraDenmark
- Target Recruit Count
- 50
- Registration Number
- NCT02612129
- Locations
- 🇺🇸
Mayo Clinic Children's Center, Rochester, Minnesota, United States
🇫🇷CHU de Montpellier, Montpellier, France
🇩🇪Villa Metabolica, Universitätsmedizin Mainz, Mainz, Germany
Arimoclomol in Sporadic Inclusion Body Myositis
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Richard Barohn, MD
- Target Recruit Count
- 24
- Registration Number
- NCT00769860
- Locations
- 🇬🇧
University College London, MRC Centre for Neuromuscular Disease, London, United Kingdom
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 38
- Registration Number
- NCT00706147
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- CytRx
- Registration Number
- NCT00561366
- Locations
- 🇺🇸
Virginia Mason Clinic - Tier 2 Site, Seattle, Washington, United States
🇺🇸Massachusetts General Hospital - Tier 1 Site, Boston, Massachusetts, United States
🇺🇸University of Kansas Medical Center - Tier 2 site, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.